A Single Centre Observational Retrospective Study Evaluation of Serum Biomarker CEA and Ca-125 as Immunotherapy Response Predictors in Metastatic Non-small Cell Lung Cancer Patients
Latest Information Update: 05 Feb 2021
Price :
$35 *
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Biomarker; Therapeutic Use
- 03 Feb 2021 New trial record
- 01 Feb 2021 Results published in the Anticancer Research